Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skul… Read more
Zimmer Biomet Holdings Inc (ZBH) - Net Assets
Latest net assets as of September 2025: $12.77 Billion USD
Based on the latest financial reports, Zimmer Biomet Holdings Inc (ZBH) has net assets worth $12.77 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($23.49 Billion) and total liabilities ($10.72 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $12.77 Billion |
| % of Total Assets | 54.35% |
| Annual Growth Rate | 14.86% |
| 5-Year Change | 2.27% |
| 10-Year Change | 27.13% |
| Growth Volatility | 163.23 |
Zimmer Biomet Holdings Inc - Net Assets Trend (1999–2024)
This chart illustrates how Zimmer Biomet Holdings Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zimmer Biomet Holdings Inc (1999–2024)
The table below shows the annual net assets of Zimmer Biomet Holdings Inc from 1999 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $12.48 Billion | -0.10% |
| 2023-12-31 | $12.49 Billion | +3.83% |
| 2022-12-31 | $12.03 Billion | -5.05% |
| 2021-12-31 | $12.67 Billion | +3.83% |
| 2020-12-31 | $12.20 Billion | -1.56% |
| 2019-12-31 | $12.39 Billion | +9.90% |
| 2018-12-31 | $11.28 Billion | -3.91% |
| 2017-12-31 | $11.74 Billion | +21.36% |
| 2016-12-31 | $9.67 Billion | -1.46% |
| 2015-12-31 | $9.81 Billion | +50.45% |
| 2014-12-31 | $6.52 Billion | +3.53% |
| 2013-12-31 | $6.30 Billion | +7.39% |
| 2012-12-31 | $5.87 Billion | +6.37% |
| 2011-12-31 | $5.51 Billion | -4.44% |
| 2010-12-31 | $5.77 Billion | +2.35% |
| 2009-12-31 | $5.64 Billion | -0.27% |
| 2008-12-31 | $5.65 Billion | +3.70% |
| 2007-12-31 | $5.45 Billion | +10.75% |
| 2006-12-31 | $4.92 Billion | +5.08% |
| 2005-12-31 | $4.69 Billion | +18.62% |
| 2004-12-31 | $3.95 Billion | +25.37% |
| 2003-12-31 | $3.15 Billion | +760.03% |
| 2002-12-31 | $366.30 Million | +365.44% |
| 2001-12-31 | $78.70 Million | -69.85% |
| 2000-12-31 | $261.00 Million | -33.25% |
| 1999-12-31 | $391.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zimmer Biomet Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1109530000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $11.10 Billion | 88.99% |
| Common Stock | $3.20 Million | 0.03% |
| Other Comprehensive Income | $-262.80 Million | -2.11% |
| Other Components | $1.63 Billion | 13.09% |
| Total Equity | $12.47 Billion | 100.00% |
Zimmer Biomet Holdings Inc Competitors by Market Cap
The table below lists competitors of Zimmer Biomet Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chow Tai Fook Jewellery Group
PINK:CJEWY
|
$18.30 Billion |
|
Tenet Healthcare Corporation
NYSE:THC
|
$18.32 Billion |
|
BWX Technologies Inc
NYSE:BWXT
|
$18.32 Billion |
|
Imperial Oil Ltd
NYSE MKT:IMO
|
$18.34 Billion |
|
Carnival Corporation & plc
PINK:CUKPF
|
$18.29 Billion |
|
Nidec Corporation
PINK:NNDNF
|
$18.28 Billion |
|
PTC Inc
NASDAQ:PTC
|
$18.27 Billion |
|
LyondellBasell Industries NV
NYSE:LYB
|
$18.22 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zimmer Biomet Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,480,500,000 to 12,468,100,000, a change of -12,400,000 (-0.1%).
- Net income of 903,800,000 contributed positively to equity growth.
- Dividend payments of 196,000,000 reduced retained earnings.
- Share repurchases of 868,000,000 reduced equity.
- Other comprehensive income decreased equity by 71,800,000.
- Other factors increased equity by 219,600,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $903.80 Million | +7.25% |
| Dividends Paid | $196.00 Million | -1.57% |
| Share Repurchases | $868.00 Million | -6.96% |
| Other Comprehensive Income | $-71.80 Million | -0.58% |
| Other Changes | $219.60 Million | +1.76% |
| Total Change | $- | -0.10% |
Book Value vs Market Value Analysis
This analysis compares Zimmer Biomet Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 45.81x to 1.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $2.02 | $92.52 | x |
| 2000-12-31 | $1.35 | $92.52 | x |
| 2001-12-31 | $0.41 | $92.52 | x |
| 2002-12-31 | $1.86 | $92.52 | x |
| 2003-12-31 | $14.88 | $92.52 | x |
| 2004-12-31 | $15.91 | $92.52 | x |
| 2005-12-31 | $18.75 | $92.52 | x |
| 2006-12-31 | $20.05 | $92.52 | x |
| 2007-12-31 | $22.95 | $92.52 | x |
| 2008-12-31 | $24.75 | $92.52 | x |
| 2009-12-31 | $26.13 | $92.52 | x |
| 2010-12-31 | $28.70 | $92.52 | x |
| 2011-12-31 | $29.18 | $92.52 | x |
| 2012-12-31 | $33.30 | $92.52 | x |
| 2013-12-31 | $36.65 | $92.52 | x |
| 2014-12-31 | $37.98 | $92.52 | x |
| 2015-12-31 | $51.69 | $92.52 | x |
| 2016-12-31 | $47.77 | $92.52 | x |
| 2017-12-31 | $57.61 | $92.52 | x |
| 2018-12-31 | $55.39 | $92.52 | x |
| 2019-12-31 | $59.93 | $92.52 | x |
| 2020-12-31 | $58.91 | $92.52 | x |
| 2021-12-31 | $60.17 | $92.52 | x |
| 2022-12-31 | $57.16 | $92.52 | x |
| 2023-12-31 | $59.52 | $92.52 | x |
| 2024-12-31 | $61.15 | $92.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zimmer Biomet Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.25%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.77%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 1.71x
- Recent ROE (7.25%) is below the historical average (21.97%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | 38.36% | 15.97% | 1.55x | 1.55x | $110.90 Million |
| 2000 | 67.43% | 16.91% | 1.74x | 2.29x | $149.90 Million |
| 2001 | 190.34% | 12.71% | 1.58x | 9.47x | $141.93 Million |
| 2002 | 70.38% | 18.78% | 1.60x | 2.34x | $221.17 Million |
| 2003 | 11.02% | 18.22% | 0.37x | 1.64x | $31.97 Million |
| 2004 | 13.74% | 18.18% | 0.52x | 1.44x | $147.55 Million |
| 2005 | 15.64% | 22.29% | 0.57x | 1.22x | $264.22 Million |
| 2006 | 16.96% | 23.87% | 0.59x | 1.21x | $342.45 Million |
| 2007 | 14.19% | 19.84% | 0.59x | 1.22x | $228.24 Million |
| 2008 | 15.02% | 20.59% | 0.57x | 1.28x | $283.57 Million |
| 2009 | 12.72% | 17.52% | 0.53x | 1.38x | $153.53 Million |
| 2010 | 10.34% | 14.14% | 0.53x | 1.39x | $19.77 Million |
| 2011 | 13.81% | 17.09% | 0.52x | 1.55x | $210.08 Million |
| 2012 | 12.88% | 16.88% | 0.50x | 1.54x | $168.91 Million |
| 2013 | 12.08% | 16.46% | 0.48x | 1.52x | $131.27 Million |
| 2014 | 11.05% | 15.41% | 0.49x | 1.48x | $68.22 Million |
| 2015 | 1.50% | 2.45% | 0.22x | 2.79x | $-834.16 Million |
| 2016 | 3.16% | 3.99% | 0.29x | 2.76x | $-660.99 Million |
| 2017 | 15.46% | 23.24% | 0.30x | 2.22x | $640.22 Million |
| 2018 | -3.36% | -4.78% | 0.33x | 2.14x | $-1.51 Billion |
| 2019 | 9.13% | 14.18% | 0.32x | 1.99x | $-107.21 Million |
| 2020 | -1.14% | -2.27% | 0.25x | 2.00x | $-1.36 Billion |
| 2021 | 3.17% | 5.88% | 0.29x | 1.85x | $-864.47 Million |
| 2022 | 1.93% | 3.33% | 0.33x | 1.75x | $-970.63 Million |
| 2023 | 8.20% | 13.85% | 0.34x | 1.72x | $-224.05 Million |
| 2024 | 7.25% | 11.77% | 0.36x | 1.71x | $-343.01 Million |
Industry Comparison
This section compares Zimmer Biomet Holdings Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zimmer Biomet Holdings Inc (ZBH) | $12.77 Billion | 38.36% | 0.84x | $18.29 Billion |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |